RT Journal Article
SR Electronic
T1 Detection of SARS-CoV-2 in the community by nucleic acid amplification testing of saliva
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21263644
DO 10.1101/2021.09.15.21263644
A1 Fronza, Filippo
A1 Groff, Nelli
A1 Martinelli, Angela
A1 Passerini, Beatrice Zita
A1 Rensi, Nicolò
A1 Cortelletti, Irene
A1 Vivori, Nicolò
A1 Adami, Valentina
A1 Helander, Anna
A1 Bridi, Simone
A1 Pancher, Michael
A1 Greco, Valentina
A1 Garritano, Sonia Iolanda
A1 Piffer, Elena
A1 Stefani, Lara
A1 De Sanctis, Veronica
A1 Bertorelli, Roberto
A1 Pancheri, Serena
A1 Collini, Lucia
A1 Quattrone, Alessandro
A1 Capobianchi, Maria Rosaria
A1 Icardi, Giancarlo
A1 Poli, Guido
A1 Caciagli, Patrizio
A1 Ferro, Antonio
A1 Pizzato, Massimo
YR 2021
UL http://medrxiv.org/content/early/2021/09/20/2021.09.15.21263644.abstract
AB Efficient wide-scale testing for SARS-CoV-2 is crucial for monitoring the incidence of the infection in the community. The gold standard for COVID-19 diagnosis is the molecular analysis of epithelial secretions from the upper respiratory system captured by nasopharyngeal (NP) swabs, which requires the intervention of trained personnel. Given the ease of collection, saliva has been proposed as a possible substitute to support testing at the population level. Here we describe the set-up of a laboratory, in an academic context, for the high-throughput screening of SARS-CoV-2 in the saliva from the community. A novel saliva collection device was designed to favour the safe and correct acquisition of the sample as well as the processivity of the downstream molecular analysis. To test the performance of the system,1025 paired saliva and nasopharyngeal samples were collected from individuals recruited at a public drive through testing facility and analysed in parallel. An overall moderate concordance (68%) between the two tests was found, with evidence that neither test can diagnose the infection in 100% of the cases. While the two tests performed equally well in symptomatic individuals, their discordance was mainly restricted to samples from convalescent individuals. The saliva test was at least as effective as NP swabs in asymptomatic individuals recruited for contact tracing. Our study, therefore, indicates that saliva testing can be a reliable tool for wide-scale COVID-19 screening in the community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from PAT (Provincia Autonoma di Trento) to the University of Trento with a contribution from APSS (Azienda Provinciale per i Servizi Sanitari, Trento) and from the University of Trento.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comitato etico per le sperimentazioni cliniche, Azienda provinciale per i servizi sanitari della Provincia autonoma di Trento. Approval obtained on March 19, 2021.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data set analyzed in this paper is available from the corresponding author on request.